Evaluation of efficacy and safety of fixed dose combination of glimepiride 2mg plus pioglitazone 15mg plus metformin SR 500mg in the management of patients with type-2 diabetes mellitus

Journal of the Indian Medical Association

Volumn 103, Issue 8, 2005, Pages 447-450

  Meshram, D M ^a,b   Langade, D G ^a,c   Kinagi, Satish B ^a,d   Naikwadi, Akram A ^a,e   Morye, Vinita ^a,f   Chopra, Dimple ^a,f  

^a GRANT MEDICAL COLLEGE   (India)

^b Urban Health Centre   (India)

^c Department of Pharmacology ^*

^d M R MEDICAL COLLEGE   (India)

^e Department of Pharmacology   (India)

^f Unichem Laboratories Ltd   (India)

Author keywords

Glycosylated haemoglobin; Triple drug combination; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INDIAN; LIPOPROTEIN BLOOD LEVEL; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 28944454274     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. King H, Rewers M. WHO Ad Hoc Diabetes Reporting Group-Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993; 16: 157-77.
2. Genuth S, Eastman R, Kahn R, et al - Implications of the United Kingdom Prospective Diabetes Study: American Diabetes Association. Diabetes Care 2002; 25: 1: S2S-32.
3. King H, Aubert RE, Herman WH - Global burden of diabetes 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-32.
4. Harris MI, Flegal KM, Cowie CC, et al - Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21: 518-26.
5. Center for Disease Control and Prevention - National Estimates and General Information on Diabetes in the United States: Diabetes Facts Sheet. Atlanta, US Department Health and Human Services, Center for Disease Control and Prevention, 1997.
6. Kannel WB, McGee DL - Diabetes and cardiovascular risk factors: The Framingham study. Circulation 1979; 59: 8-13.
7. Harrigan RA - Annals of Emergency Medicine. Vol 38. No 1, July 2001.
8. Riddle M - Combining sulfonylureas and other oral agents. Am J Med 2000; 17: 15s-22s.
9. Turner RC, Cull A, Frighi V, Holman RR - Glycemic control with diet, sulphonylurea, metformin or insulin in patients with type 2 diabetes. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-12.
10. UK Prospective Diabetes Study (UKPDS) Group - Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
11. Ovalle F, Bell DS - Triple oral antidibetic therapy in type 2 diabetes mellitus. Endocr Pract 1998; 4: 146-7.
12. Ohkubo Y, Kishikawa H, Raki E et al - Intensive insulin therapy prevents the, progression of diabetic microvascular complications in Japanese patients with non insulin dependent diabetes mellitus; a randomized, prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17.